Unsurprisingly, given the established interrelation between FXI activation and the presence of material, a phase II clinical trial has begun assessing Xisomab 3G3 (AB023) versus placebo for the prevention of catheter-related thrombosis in cancer patients. Here, F11 is linked to cancer.